Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.11-01

Agios Pharmaceuticals (NASDAQ:AGIO) Third Quarter 2024 Results Key Financial Results Revenue: US$8.96m (up 21% from 3Q 2023). Net income: US$947.9m (up from US$91.3m loss in 3Q 2023). EPS: US$16.65 (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480909885?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-11-01 20:57","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480909885","market":"us","top_or_hot":-1,"title":"Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag","media":"Simply Wall St.","content":"<div>\n<p>Agios Pharmaceuticals (NASDAQ:AGIO) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$8.96m (up 21% from 3Q 2023).\nNet income: US$947.9m (up from US$91.3m loss in 3Q 2023).\nEPS: US$16.65 (...</p>\n\n<a href=\"https://finance.yahoo.com/news/agios-pharmaceuticals-third-quarter-2024-125714675.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/agios-pharmaceuticals-third-quarter-2024-125714675.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agios Pharmaceuticals (NASDAQ:AGIO) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$8.96m (up 21% from 3Q 2023).\nNet income: US$947.9m (up from US$91.3m loss in 3Q 2023).\nEPS: US$16.65 (...</p>\n\n<a href=\"https://finance.yahoo.com/news/agios-pharmaceuticals-third-quarter-2024-125714675.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIO","symbol_name":"Agios Pharmaceuticals, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/agios-pharmaceuticals-third-quarter-2024-125714675.html","article_id":"2480909885","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480909885","pubTimestamp":1730465834,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqGS:AGIO Earnings and Revenue Growth November 1st 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 5.7%. Earnings per share  exceeded analyst estimates by 87%.Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are down 1.5% from a week ago.You still need to take note of risks, for example - Agios Pharmaceuticals has   2 warning signs    we think you should know about.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"Agios Pharmaceuticals 2024年第三季度收益：每股收益超出预期，收入滞后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1},"content_text":"Agios Pharmaceuticals (NASDAQ:AGIO) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$8.96m (up 21% from 3Q 2023).\nNet income: US$947.9m (up from US$91.3m loss in 3Q 2023).\nEPS: US$16.65 (up from US$1.64 loss in 3Q 2023).\n\n\n\n\n  NasdaqGS:AGIO Earnings and Revenue Growth November 1st 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nAgios Pharmaceuticals EPS Beats Expectations, Revenues Fall Short\n Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 87%. \n Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. \nPerformance of the American Biotechs industry.\n The company's shares are down 1.5% from a week ago. \nRisk Analysis\n You still need to take note of risks, for example - Agios Pharmaceuticals has   2 warning signs  (and 1 which is a bit unpleasant)  we think you should know about. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480909885"}